Unity Biotechnology Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 4.4yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22CEO
Unity Biotechnology has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Head of Corporate Development | 4.9yrs | US$926.68k | 0.42% $ 7.6k | |
| Chief Legal Officer & Head of Operations | 4.3yrs | US$903.03k | 0.21% $ 3.7k | |
| Founder | 14.5yrs | no data | no data | |
| Chief Scientist | 4.4yrs | no data | no data | |
| Chief Strategy Officer | 1yr | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: UNBX's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 10.3yrs | US$66.42k | 0.0059% $ 106.4 | |
| Independent Chairman | 9.5yrs | US$88.92k | 0.13% $ 2.3k | |
| Independent Director | 6.6yrs | US$59.92k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 3.2yrs | US$71.92k | 0% $ 0 |
Experienced Board: UNBX's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/28 13:53 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Andrew Fein | H.C. Wainwright & Co. |
| Matthew Caufield | H.C. Wainwright & Co. |